Cargando…

An Examination of State and Federal Opioid Analgesic and Continuing Education Policies: 2016–2018

INTRODUCTION: Opioid overdose deaths in the United States have climbed sharply over the past two decades. Simultaneously, increased awareness of inadequately treated chronic pain has resulted in increased opioid analgesic prescribing. The correlation between these two phenomena has led policymakers...

Descripción completa

Detalles Bibliográficos
Autores principales: Duensing, Kathryn, Twillman, Robert, Ziegler, Stephen, Cepeda, M Soledad, Kern, David, Salas, Maribel, Wedin, Gregory
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7534855/
https://www.ncbi.nlm.nih.gov/pubmed/33061558
http://dx.doi.org/10.2147/JPR.S267448
_version_ 1783590376799469568
author Duensing, Kathryn
Twillman, Robert
Ziegler, Stephen
Cepeda, M Soledad
Kern, David
Salas, Maribel
Wedin, Gregory
author_facet Duensing, Kathryn
Twillman, Robert
Ziegler, Stephen
Cepeda, M Soledad
Kern, David
Salas, Maribel
Wedin, Gregory
author_sort Duensing, Kathryn
collection PubMed
description INTRODUCTION: Opioid overdose deaths in the United States have climbed sharply over the past two decades. Simultaneously, increased awareness of inadequately treated chronic pain has resulted in increased opioid analgesic prescribing. The correlation between these two phenomena has led policymakers to posit that they are causally linked, and to implement policy changes supporting safe opioid prescribing. PURPOSE: To evaluate the impact of its Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS) program, the US Food and Drug Administration (FDA) requested the opioid manufacturers responsible for implementing that program provide information regarding opioid policy changes from 2016 to 2018. FDA also requested a survey of state requirements for pain and opioid prescribing continuing education (CE), the number of prescribers affected by those requirements, the extent to which a REMS-compliant CE program would meet each state’s requirements, and the number of relevant CE programs available. RESULTS: Results indicate that 527 federal and state opioid-related policies (statutes, rules/regulations, and guidelines) were approved during the 2016–2018 study period. While the largest number of these policies focused on prescription drug monitoring programs, 170 specifically imposed limits on opioid prescribing and an additional 35 specifically referred to, or incorporated, the Centers for Disease Control and Prevention opioid prescribing guideline. We also found that 46 states and the District of Columbia mandated some amount of pain or opioid prescribing CE for prescribers renewing their licenses. These mandates potentially affected as many as 1.7 million prescribers. In 69% of cases, a REMS-compliant CE program would fully meet the state mandates for various types of prescribers. CONCLUSION: The severity and complexity of the problems of pain management and opioid overdose have led to large-scale intervention by policymakers. Assessing the impact of these changes is difficult, at best, but will be necessary if interventions are to be refined to increase their effectiveness.
format Online
Article
Text
id pubmed-7534855
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-75348552020-10-14 An Examination of State and Federal Opioid Analgesic and Continuing Education Policies: 2016–2018 Duensing, Kathryn Twillman, Robert Ziegler, Stephen Cepeda, M Soledad Kern, David Salas, Maribel Wedin, Gregory J Pain Res Original Research INTRODUCTION: Opioid overdose deaths in the United States have climbed sharply over the past two decades. Simultaneously, increased awareness of inadequately treated chronic pain has resulted in increased opioid analgesic prescribing. The correlation between these two phenomena has led policymakers to posit that they are causally linked, and to implement policy changes supporting safe opioid prescribing. PURPOSE: To evaluate the impact of its Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS) program, the US Food and Drug Administration (FDA) requested the opioid manufacturers responsible for implementing that program provide information regarding opioid policy changes from 2016 to 2018. FDA also requested a survey of state requirements for pain and opioid prescribing continuing education (CE), the number of prescribers affected by those requirements, the extent to which a REMS-compliant CE program would meet each state’s requirements, and the number of relevant CE programs available. RESULTS: Results indicate that 527 federal and state opioid-related policies (statutes, rules/regulations, and guidelines) were approved during the 2016–2018 study period. While the largest number of these policies focused on prescription drug monitoring programs, 170 specifically imposed limits on opioid prescribing and an additional 35 specifically referred to, or incorporated, the Centers for Disease Control and Prevention opioid prescribing guideline. We also found that 46 states and the District of Columbia mandated some amount of pain or opioid prescribing CE for prescribers renewing their licenses. These mandates potentially affected as many as 1.7 million prescribers. In 69% of cases, a REMS-compliant CE program would fully meet the state mandates for various types of prescribers. CONCLUSION: The severity and complexity of the problems of pain management and opioid overdose have led to large-scale intervention by policymakers. Assessing the impact of these changes is difficult, at best, but will be necessary if interventions are to be refined to increase their effectiveness. Dove 2020-10-01 /pmc/articles/PMC7534855/ /pubmed/33061558 http://dx.doi.org/10.2147/JPR.S267448 Text en © 2020 Duensing et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Duensing, Kathryn
Twillman, Robert
Ziegler, Stephen
Cepeda, M Soledad
Kern, David
Salas, Maribel
Wedin, Gregory
An Examination of State and Federal Opioid Analgesic and Continuing Education Policies: 2016–2018
title An Examination of State and Federal Opioid Analgesic and Continuing Education Policies: 2016–2018
title_full An Examination of State and Federal Opioid Analgesic and Continuing Education Policies: 2016–2018
title_fullStr An Examination of State and Federal Opioid Analgesic and Continuing Education Policies: 2016–2018
title_full_unstemmed An Examination of State and Federal Opioid Analgesic and Continuing Education Policies: 2016–2018
title_short An Examination of State and Federal Opioid Analgesic and Continuing Education Policies: 2016–2018
title_sort examination of state and federal opioid analgesic and continuing education policies: 2016–2018
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7534855/
https://www.ncbi.nlm.nih.gov/pubmed/33061558
http://dx.doi.org/10.2147/JPR.S267448
work_keys_str_mv AT duensingkathryn anexaminationofstateandfederalopioidanalgesicandcontinuingeducationpolicies20162018
AT twillmanrobert anexaminationofstateandfederalopioidanalgesicandcontinuingeducationpolicies20162018
AT zieglerstephen anexaminationofstateandfederalopioidanalgesicandcontinuingeducationpolicies20162018
AT cepedamsoledad anexaminationofstateandfederalopioidanalgesicandcontinuingeducationpolicies20162018
AT kerndavid anexaminationofstateandfederalopioidanalgesicandcontinuingeducationpolicies20162018
AT salasmaribel anexaminationofstateandfederalopioidanalgesicandcontinuingeducationpolicies20162018
AT wedingregory anexaminationofstateandfederalopioidanalgesicandcontinuingeducationpolicies20162018
AT duensingkathryn examinationofstateandfederalopioidanalgesicandcontinuingeducationpolicies20162018
AT twillmanrobert examinationofstateandfederalopioidanalgesicandcontinuingeducationpolicies20162018
AT zieglerstephen examinationofstateandfederalopioidanalgesicandcontinuingeducationpolicies20162018
AT cepedamsoledad examinationofstateandfederalopioidanalgesicandcontinuingeducationpolicies20162018
AT kerndavid examinationofstateandfederalopioidanalgesicandcontinuingeducationpolicies20162018
AT salasmaribel examinationofstateandfederalopioidanalgesicandcontinuingeducationpolicies20162018
AT wedingregory examinationofstateandfederalopioidanalgesicandcontinuingeducationpolicies20162018